Skip to main content
. 2017 Apr 5;7:45703. doi: 10.1038/srep45703

Table 2. Results of univariate analysis for different regorafenib-related off-target effects on patients’ outcome in terms of DCR, mPFS and mOS.

  DCR p PFS (months) HR (95% CI) p OS (months) HR (95% CI) p
HFSR
Grade ≥2: 41 (28%) 47% 0.0269 3.2 0.73 (0.51–1.04) 0.10 6.59 0.80 (0.52–1.25) 0.35
Grade 0–1: 103 (72%) 25% 2.5 5.96
SKIN RASH
Grade ≥2: 38 (26%) 55% 0.00387 3.67 0.60 (0.420.86) 0.0096 10.36 0.54 (0.360.86) 0.0085
Grade 0–1: 106 (74%) 21% 2.68 5.04
HYPERTENSION
Grade ≥2: 29 (20%) 48% 0.0526 4.32 0.61 (0.410.89) 0.0197 7.18 0.71 (0.45–1.13) 0.188
Grade 0–1: 115 (80%) 27% 2.65 5.04
FATIGUE Yes/No
Grade ≥2: 65 (45%) 32% 1.0000 2.85 0.93 (0.66–1.32) 0.716 7.18 0.76 (0.50–1.14) 0.195
Grade 0–1: 79 (55%) 30% 2.68 6.03
AST/ALT ELEVATION
Grade ≥2: 18 (12%) 43% 0.29 3.01 1.11 (0.65–1.89) 0.68 4.16 1.60 (0.83–3.10) 0.08
Grade 0–1: 126 (88%) 29% 2.78 6.32
BILIRUBIN INCREASE
Grade ≥2: 15 (10%) 23% 0.75 2.82 1.42 (0.75–2.69) 0.20 8.98 1.21 (0.63–2.33) 0.52
Grade 0–1: 129 (90%) 32% 2.78 6.03
HYPOTHYROIDISM
Grade ≥2: 13 (9%) 71% 0.03 7.96 0.56 (0.34–0.93) 0.0635 NR 0.10 (0.050.19) 0.0042
Grade 0–1: 131 (91%) 28% 2.75 5.83
DIARRHEA
Grade ≥2: 21 (15%) 53% 0.0489 5.11 0.54 (0.360.81) 0.0130 11.41 0.53 (0.320.88) 0.0440
Grade 0-1: 123 (85%) 27% 2.65 5.27

DCR = disease control rate, PFS = progression-free survival, HR = Hazard ratio, CI = confidence interval, OS = overall survival, HFSR = hand and foot skin reaction, AST = Aspartate Aminotransferase, ALT = alanine aminotransferase.